NEO214 is an autophagy inhibitor obtained by covalently conjugating rolipram, a PDE4 inhibitor, with perillyl alcohol. It possesses anticancer activity and blood-brain barrier (BBB) permeability, blocks autophagosome-lysosome fusion, thereby inhibiting autophagic flux and inducing glioma cell death, which is associated with mTOR activation and aggregation of the transcription factor TFEB. NEO214 inhibits macroautophagy/autophagy in glioblastoma cells and has the potential to overcome chemoresistance in glioblastoma.
Molecular Weight:
453.57
Purity:
95.63%
CAS Number:
[1361198-80-2]
Formula:
C27H35NO5
Target:
mTOR|||Autophagy
T86992
* VAT and and shipping costs not included. Errors and price changes excepted
